Biocon’s shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to ’Buy’ with a target price of ₹430, ...

Indian stock market rebounded on January 14, marking a recovery after four consecutive sessions of selling pressure that had ...

HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...

Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...

So, buy-on decline to continue over here, but just for intraday perspective, overall swings will continue and one needs to be ...

The stock has gained 9.66% in the last month, 7.99% over the past six months, and an impressive 37.98% in the last year.

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Biocon's share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE).

Biocon share price rose 4.5% following US FDA clearance for its Malaysian insulin facility, resolving a regulatory bottleneck ...

Indian shares rose on Tuesday, led by a rally in energy stocks after a brokerage upgraded ONGC and as Reliance recovered some ...

Pharma companies in India are expected to report healthy earnings growth in the just-concluded October-December quarter, ...